Drug intelligence / Profile preview

IMYX-3

Development stage: Preclinical
Lead developer: Immunyx
Modality: Nanoparticles → Drug Delivery Systems

Overview

IMYX-3 is a first-in-class neutrophil-modifying drug candidate developed by Immunyx Pharma using its proprietary Targeted Neutrophil Nanoparticle (TENNs) platform. The therapy is designed to modulate neutrophil activity at the site of inflammation to treat chronic inflammatory diseases without depleting the cells or causing systemic neutropenia. By addressing neutrophil-driven pathology, IMYX-3 aims to provide a therapeutic option for conditions where no FDA-approved neutrophil-targeted therapies currently exist. IMYX-3 is currently being evaluated in preclinical studies for Chronic Obstructive Pulmonary Disease (COPD) and is in IND-enabling stages for Inflammatory Bowel Disease (IBD).

Targets

RAB27A (Ras-related protein Rab-27A)

Beyond the preview

Go deeper on IMYX-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMYX-3.

Explore the full profile